| ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets AJ Souers, JD Leverson, ER Boghaert, SL Ackler, ND Catron, J Chen, ... Nature medicine 19 (2), 202-208, 2013 | 3082 | 2013 |
| Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study P Fenaux, GJ Mufti, E Hellstrom-Lindberg, V Santini, C Finelli, ... The lancet oncology 10 (3), 223-232, 2009 | 3007 | 2009 |
| Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial M Hallek, K Fischer, G Fingerle-Rowson, AM Fink, R Busch, J Mayer, ... The Lancet 376 (9747), 1164-1174, 2010 | 2397 | 2010 |
| Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia AW Roberts, MS Davids, JM Pagel, BS Kahl, SD Puvvada, JF Gerecitano, ... New England Journal of Medicine 374 (4), 311-322, 2016 | 2051 | 2016 |
| iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL M Hallek, BD Cheson, D Catovsky, F Caligaris-Cappio, G Dighiero, ... Blood, The Journal of the American Society of Hematology 131 (25), 2745-2760, 2018 | 1638 | 2018 |
| International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with> 30% blasts H Dombret, JF Seymour, A Butrym, A Wierzbowska, D Selleslag, JH Jang, ... Blood, The Journal of the American Society of Hematology 126 (3), 291-299, 2015 | 1318 | 2015 |
| Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial G Salles, JF Seymour, F Offner, A López-Guillermo, D Belada, L Xerri, ... The Lancet 377 (9759), 42-51, 2011 | 1243 | 2011 |
| Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia P Fenaux, GJ Mufti, E Hellström-Lindberg, V Santini, N Gattermann, ... Journal of clinical oncology 28 (4), 562-569, 2010 | 1166 | 2010 |
| Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project KR Carson, AM Evens, EA Richey, TM Habermann, D Focosi, JF Seymour, ... Blood, The Journal of the American Society of Hematology 113 (20), 4834-4840, 2009 | 1053 | 2009 |
| Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP … S Branford, Z Rudzki, S Walsh, I Parkinson, A Grigg, J Szer, K Taylor, ... Blood 102 (1), 276-283, 2003 | 993 | 2003 |
| Pulmonary alveolar proteinosis: progress in the first 44 years JF Seymour, JJ Presneill American journal of respiratory and critical care medicine 166 (2), 215-235, 2002 | 985 | 2002 |
| Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia JF Seymour, TJ Kipps, B Eichhorst, P Hillmen, J D’Rozario, S Assouline, ... New England Journal of Medicine 378 (12), 1107-1120, 2018 | 961 | 2018 |
| Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease AW Roberts, JF Seymour, JR Brown, WG Wierda, TJ Kipps, SL Khaw, ... Journal of Clinical Oncology 30 (5), 488, 2012 | 940 | 2012 |
| Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study S Stilgenbauer, B Eichhorst, J Schetelig, S Coutre, JF Seymour, T Munir, ... The lancet oncology 17 (6), 768-778, 2016 | 937 | 2016 |
| Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma LE Abrey, TT Batchelor, AJM Ferreri, M Gospodarowicz, EJ Pulczynski, ... Journal of clinical oncology 23 (22), 5034-5043, 2005 | 897 | 2005 |
| Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study DM Ross, S Branford, JF Seymour, AP Schwarer, C Arthur, DT Yeung, ... Blood, The Journal of the American Society of Hematology 122 (4), 515-522, 2013 | 849 | 2013 |
| Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial K Fischer, J Bahlo, AM Fink, V Goede, CD Herling, P Cramer, ... Blood, The Journal of the American Society of Hematology 127 (2), 208-215, 2016 | 803 | 2016 |
| Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma MS Davids, AW Roberts, JF Seymour, JM Pagel, BS Kahl, WG Wierda, ... Journal of Clinical Oncology 35 (8), 826, 2017 | 750 | 2017 |
| Obinutuzumab for the first-line treatment of follicular lymphoma R Marcus, A Davies, K Ando, W Klapper, S Opat, C Owen, E Phillips, ... New England Journal of Medicine 377 (14), 1331-1344, 2017 | 744 | 2017 |
| The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee E Campo, ES Jaffe, JR Cook, L Quintanilla-Martinez, SH Swerdlow, ... Blood, The Journal of the American Society of Hematology 140 (11), 1229-1253, 2022 | 729 | 2022 |
